Latest Breaking News On - Mesenchymal stromal cell therapy - Page 1 : comparemela.com

Key Highlights: Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost to facilitate the trial and has full commercial rights There are approximately 130,000 kidney transplants around the world each year. Kidney transplantation is life-saving in patients with chronic renal failure and frees the patient from the need for dialysis. Currently, lifelong immune suppressive therapy is required in renal transplant patients to reduce the risk of rejection. This can lead to increased risk of infections and cancer and the main anti-rejection drugs are also directly toxic to the kidneys In previous clinical trials, mesenchymal stromal/stem cells have shown potential to enable the early withdrawal of anti-rejection drugs in renal transplant recipients without increased rejection and wi

Cynata cymerus mscsRoss macdonaldCymerus mscsLeiden university medical centerHead of the department internal medicineDepartment of nephrologyCynata therapeutics limitedKey highlightsMesenchymal stromal cell therapyRenal transplant recipientsTon rabelinkInternal medicineChief executive officerProfessor rabelinkManaging directorClinical trial